However, taking into account the results of the ineffective higher doses of sitagliptin that we observed in e-NOS and TRPC-1 protein expression, this issue requires further investigations in the near future, and this drug can be considered for the treatment of ischemic diseases at a higher level, only after clarifying the molecular mechanisms underlying these doses. The gene discussed is NOS2; the disease is ischemic disease.